45 trials changed in the last 30 days: 0 stopped, 11 with notable changes, 34 with minor changes only.
Primary endpoint(s) modified
Janssen Scientific Affairs, LLCNot specified NCT04372108 Registry history of NCT04372108 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 19 locations; and 1 more change in the last 30 days
Janssen Research & Development, LLCPhase 3 NCT07665450 Registry history of NCT07665450 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 5 locations; Start date changed from estimate of Sep 28, 2026 to Sep 16, 2026
Janssen Research & Development, LLCPhase 2 NCT07832292 Registry history of NCT07832292 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Johnson & Johnson Vision Care, Inc.Not applicable NCT07819305 Registry history of NCT07819305 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Johnson & Johnson Vision Care, Inc.Not applicable NCT07788521 Registry history of NCT07788521 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 18, 2026 to Sep 14, 2026
Janssen Research & Development, LLCNot specified NCT07822529 Registry history of NCT07822529 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 20, 2026
Janssen Research & Development, LLCPhase 3 NCT04630028 Registry history of NCT04630028 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 15, 2026
Johnson & Johnson Vision Care, Inc.Not applicable NCT07076160 Registry history of NCT07076160 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 6, 2026
Janssen Research & Development, LLCPhase 3 NCT05518149 Registry history of NCT05518149 on ClinicalTrials.gov (opens the registry)
Results posted: Sep 28, 2026
Janssen Research & Development, LLCPhase 3 NCT04899336 Registry history of NCT04899336 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 30, 2026 to Oct 30, 2026
Also in this update: Study completion pushed from Sep 30, 2029 to Oct 30, 2029
Janssen Sciences Ireland UCNot specified NCT07746765 Registry history of NCT07746765 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 539 participants (planned 700)
Janssen Research & Development, LLCPhase 3 NCT01804686 Registry history of NCT01804686 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Janssen Research & Development, LLCPhase 2 NCT07266441 Registry history of NCT07266441 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion moved earlier from Nov 21, 2028 to Feb 9, 2028; Final enrollment: 85 participants (planned 155)
Janssen Research & Development, LLCPhase 1 NCT06651229 Registry history of NCT06651229 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 29, 2026 to Jul 21, 2026; Final enrollment: 6 participants (planned 10)
Janssen Research & Development, LLCPhase 1 NCT07295951 Registry history of NCT07295951 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 11, 2028 to Aug 17, 2028
Janssen Research & Development, LLCPhase 1/2 NCT06800313 Registry history of NCT06800313 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 240 → 276 participants
And 2 more changes in the last 30 days
Janssen Research & Development, LLCPhase 1 NCT06768489 Registry history of NCT06768489 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 142 → 252 locations
Janssen Research & Development, LLCPhase 3 NCT07577843 Registry history of NCT07577843 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 170 → 279 locations
Janssen Research & Development, LLCPhase 3 NCT07577856 Registry history of NCT07577856 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 39 → 45 locations
Janssen Research & Development, LLCPhase 3 NCT07573176 Registry history of NCT07573176 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 262 → 266 locations
Janssen Research & Development, LLCPhase 3 NCT06852222 Registry history of NCT06852222 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 151 → 173 locations
Janssen Research & Development, LLCPhase 3 NCT07518186 Registry history of NCT07518186 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 152 → 158 locations
Also in this update: Study completion pushed from Jul 20, 2029 to Jun 7, 2030
Janssen Research & Development, LLCPhase 3 NCT07225946 Registry history of NCT07225946 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 39 → 44 locations
Janssen Research & Development, LLCPhase 3 NCT07227454 Registry history of NCT07227454 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 144 → 150 locations
Janssen Research & Development, LLCPhase 3 NCT07258511 Registry history of NCT07258511 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 15 → 22 locations
Janssen Research & Development, LLCPhase 3 NCT07716098 Registry history of NCT07716098 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 249 → 260 locations
Janssen Research & Development, LLCPhase 3 NCT07438496 Registry history of NCT07438496 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 9 → 38 locations
Janssen Research & Development, LLCPhase 2 NCT07589634 Registry history of NCT07589634 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 17 → 20 locations
Janssen Research & Development, LLCPhase 2 NCT07149857 Registry history of NCT07149857 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 20 → 23 locations
Janssen Research & Development, LLCPhase 2 NCT07586202 Registry history of NCT07586202 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 41 → 44 locations
Janssen Research & Development, LLCPhase 1 NCT06150157 Registry history of NCT06150157 on ClinicalTrials.gov (opens the registry)
Primary completion moved earlier from Sep 15, 2025 to Aug 1, 2025
Janssen Research & Development, LLCPhase 3 NCT05083169 Registry history of NCT05083169 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Apr 15, 2027 to Dec 15, 2027
Janssen Research & Development, LLCPhase 3 NCT06559306 Registry history of NCT06559306 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 11, 2028 to Nov 27, 2028
Janssen Research & Development, LLCPhase 2/3 NCT05327114 Registry history of NCT05327114 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 31, 2030 to May 11, 2031
Janssen Research & Development, LLCPhase 1/2 NCT05379595 Registry history of NCT05379595 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Apr 7, 2027 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT05050097 Registry history of NCT05050097 on ClinicalTrials.gov (opens the registry)
Study completion pushed from May 3, 2027 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT05338775 Registry history of NCT05338775 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Jun 7, 2029 to Nov 30, 2027
Johnson & Johnson Enterprise Innovation Inc.Phase 1 NCT06116786 Registry history of NCT06116786 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Apr 7, 2027 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT04108195 Registry history of NCT04108195 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Nov 16, 2026 to Sep 2, 2026
Janssen Research & Development, LLCPhase 1 NCT06618001 Registry history of NCT06618001 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 30, 2028 to Dec 29, 2028
Janssen Research & Development, LLCPhase 1 NCT06788509 Registry history of NCT06788509 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2026 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT02609776 Registry history of NCT02609776 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Mar 3, 2027 to Jun 30, 2027
Janssen Research & Development, LLCPhase 1 NCT05453903 Registry history of NCT05453903 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 9, 2029 to Jun 28, 2030
Janssen Research & Development, LLCNot specified NCT07309445 Registry history of NCT07309445 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 29, 2027 to Nov 30, 2027
Janssen Cilag S.A.S.Not specified NCT06299540 Registry history of NCT06299540 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-22 | NCT07890285 A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea | Not Yet Recruiting | |
| 2026-10-01 | NCT07851207 A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel… | Not Yet Recruiting |
| Phase 1 | 47 | |
| Phase 1/2 | 12 | |
| Phase 2 | 30 | |
| Phase 2/3 | 7 | |
| Phase 3 | 71 | |
| Phase 4 | 6 |
Multiple Myeloma (32) · Crohn's Disease (22) · Prostate Cancer (22) · Psoriasis (22) · Ulcerative Colitis (20) · Lung Cancer (17) · Non-Small Cell Lung Cancer (NSCLC) (17) · Bladder Cancer (13) · Psoriatic Arthritis (13) · Leukemia (12)